Sophiris reports top-line extension data for BPH candidate
This article was originally published in Scrip
Executive Summary
Sophiris Bio has released positive top-line data from the 12-month follow-up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia (BPH) in the Phase IIb TRIUMPH study.